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Background/Aims: The Barcelona Clinic Liver Cancer (BCLC) staging system is logical for the staging and treatment of 
hepatocellular carcinoma (HCC) because it was based on survival data. This study evaluated the applicability of the BCLC 
staging system and reasons for divergence from BCLC-recommended treatments in Korean HCC patients. Methods: One 
hundred and sixty consecutive HCC patients were prospectively enrolled. Treatments were generally recommended according 
to the guideline of the American Association for the Study of Liver Diseases, but patients were also informed about alternative 
treatments. The final decision was made with patient agreement, and was based on the doctor’s preferences when a patient was 
unable to reach a decision. Results: There were 2 (1%), 101 (64%), 20 (12.5%), 34 (21.5%), and 3 (1%) patients with very early-, 
early-, intermediate-, advanced-, and terminal-stage disease, respectively. Only 64 patients (40%) were treated according to 
BCLC recommendations. The treatment deviated from BCLC recommendations in 68% (69/101) and 79% (27/34) of patients 
with early and advanced stage, respectively. The main causes of deviation were refusal to undergo surgery, the presence of an 
indeterminate malignancy nodule, the absence of a suitable donor, or financial problems. Conclusions: Donor shortage, financial 
problems, the relatively limited efficacy of molecular targeting agents, and the presence of an indeterminate nodule were the 
main causes of deviation from BCLC recommendations. Even after excluding cases in which decisions were made by patient 
preference, only 66% of the HCC patients were treated according to BCLC recommendations. Treatment guidelines that reflect 
the Korean situation are mandatory for HCC patients. (Korean J Hepatol 2011;17:113-119)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most common 
malignant tumor and the second leading cause of cancer death in 
Korea. Recently, the principles of HCC therapy have changed 
rapidly due to the increased detection of early HCC and the 
therapeutic modality advancements made, and as a result, various 
staging systems and treatment options are currently used. HCC is 
unique because in addition to cancer stage underlying liver 
function substantially affects prognosis. Furthermore, no global 
consensus has been reached regarding the application of the 
several HCC staging systems, which include the Tumor Node 
Metastasis (TNM) staging system,
1 the Okuda staging system,
2 
the Barcelona Clinic Liver Cancer (BCLC) staging system,
3,4 the 
Cancer of Liver Italian Program (CLIP) staging system,
5 Group 
d’Etude et de Traitement du Carcinome Hepatocellulaire 
(GRETCH) scoring system,
6 the Japanese Integrated Staging 
(JIS) score,
7 and Tokyo scoring system.
8
The BCLC staging system was proposed and has been 
validated by several groups in the United States and Europe 114  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
Table 1. The BCLC staging classification for hepatocellular carcinoma
Stage Tumor status Liver function status (CTP) PST
Very early (0) Single/≤ 2 cm without portal HTN
Carcinoma in situ
A0
Early (A) Single
≤ 3 tumors/each ≤ 3 cm
A-B 0
Intermediate (B) Large multinodular A-B 0
Advanced (C) Vascular invasion or extrahepatic spread A-B 1-2
Terminal (D) Any C 3-4
Adopted from references 3 and 4.
CTP, Child-Turcotte-Pugh; HTN, hypertension; PST, performance status.
to offer the best means of stage classification and treatment 
guidance for HCC. Accordingly, the BCLC staging system 
is viewed as being necessary for clinical trials and the 
reporting of clinical data. However, although this staging 
system was developed using an evidence-based approach, its 
application can be problematic because of differences bet-
ween countries in terms of available medical resources, the 
lack of a broad consensus on its cost-effectiveness, the 
priority of surgical treatment, or because the tumor stage can 
be indeterminate as the BCLC system is based on clinical 
and radiological staging.  
Therefore, the aims of this prospective study were to 
evaluate whether the BCLC staging system and its treatment 
guidelines are applicable in the majority of Korean HCC 
patients, and to identify causes of discrepancies.
MATERIALS AND METHODS
Patients
Between December 2007 and December 2008, 244 patients 
with at least one hepatic mass who were admitted to one 
hepatologist at the Asan Medical Center were prospectively 
enrolled. HCC was diagnosed using the noninvasive diagnostic 
criteria of the American Association for the Study of Liver 
Diseases (AASLD) proposed in 2005 or by histopathological 
examination. Of these 244 patients, 160 patients were finally 
diagnosed to have HCC, and these patients constituted the 
study cohort. 
Methods
The determination of BCLC stage
To determine BCLC stages, we investigated tumor size 
and number, liver function test, prothrombin time, performance 
status, and cancer-related symptoms. Portal hypertension 
was defined by the presence of esophagogastric varices by 
esophagogastroduodenal endoscopy, ascites, or splenomegaly 
and a platelet count <100,000/mm
3. All patients underwent 
four-phase dynamic computed tomography (CT), chest CT, 
and a bone scan for staging. In cases with another intrahepatic 
nodule not typical of HCC by dynamic CT, evaluations were 
made by dynamic magnetic resonance imaging (MRI) or 
biopsy, if the additional nodule was deemed to be capable of 
affecting the choice of treatment modality. In cases with an 
extrahepatic lesion larger than 1 cm, evaluations were conducted 
by positron emission tomography (PET)-CT or biopsy, and 
when biopsy, dynamic MRI, or PET-CT failed to show HCC 
or typical findings of HCC (arterial enhancement and 
portal/delayed washout by dynamic MRI, or hot uptake by 
PET-CT), nodules were classified ‘indeterminate’ and 
followed. Initial tumor staging was performed based on the 
assumption that these nodules were not HCC. According to 
the status of HCC at initial diagnosis, HCC patients were 
classified as 0 (very early), A (early), B (intermediate), C 
(advanced), or D (terminal) using BCLC staging system 
(Table 1). Final HCC stages were determined after a 
follow-up examination. If the indeterminate nodules grew or 
then showed typical findings of HCC, they were presumed 
to be HCC and tumor stages were subsequently modified. 
Determination of treatment options
After determining BCLC stage, the hepatologist in 
charge, a surgeon, and radiologists discussed whether the 
treatment option recommended by the BCLC staging system 
was technically feasible. When the recommended treatment 
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Table 2. Baseline characteristics of the study population
Characteristics N=160
Age (years, mean±SD) 56.7±9.9
Sex, n (%)
  Male 131 (82%)
  Female 29 (18%)
Etiology, n (%)
  HBV 123 (77%)
  HCV 15 (9%)
  HBV and HCV 2 (1%)
  Alcohol 9 (6%)
  Undetermined 11 (7%)
Child-Turcotte-Pugh class, n (%)
  A 137 (86%)
  B 22 (13%)
  C1 ( 1 % )
HBV, hepatitis B virus; HCV, hepatitis C virus.
presence of comorbidity, the cases concerned were regarded 
to represent deviations from the recommended BCLC 
treatment. Patients were then informed of the standard 
treatment option as recommended by the BCLC, and of its 
advantages and disadvantages, including treatment outcomes, 
treatment-related morbidities, and cost. The patients were 
also informed of the details of alternative treatments. More 
specifically, we explained the details of: surgical resection 
and radiofrequency ablation (RFA) for stage 0; surgical 
resection, liver transplantation (LT), and RFA for stage A; 
transcatheter arterial chemoembolization (TACE) for stage 
B; and of sorafenib or some other targeing agent, systemic 
chemotherapy, TACE, TACE plus radiation therapy (RT) for 
stage C. Patients who had a single HCC in BCLC A were 
recommended surgical resection if they were non-cirrhotic 
or had cirrhosis but had well preserved liver function, 
normal bilirubin and hepatic vein pressure gradient <10 
mmHg. If patients with HCC corresponding to the Milan 
criteria showed increased portal pressure or bilirubin, they 
were recommended LT. However, if patients with a single 
HCC or up to three nodules lesser than 3 cm in diameter had 
portal hypertension or increased bilirubin, they were 
recommended RFA. Child-Turcotte-Pugh (CTP) B patients 
in BCLC stage C were informed of sorafenib, but it was not 
recommended as a standard therapy because previous 
studies included a small number of patients in CTP B 
class.
9,10 Patients with an indeterminate nodule, were 
informed of the possibility that the nodule could be HCC. 
Treatment was recommended based on the assumption that 
these lesions were benign. Nevertheless, patients were also 
informed of the advantages and disadvantages of each 
treatment option with respect to potential nodule benignity 
or malignancy. Final treatment decisions were principally 
made by patients. However, decisions were made by the 
doctor in charge if a patient could not decide or hesitated to 
accept the recommended treatment, which usually occurred 
when there was a financial problem. For patients with 1
st or 
2
nd portal vein (PV) branch invasion with a liver function of 
CTP A and a tumor size of less than half total liver volume 
that refused or hesitated to use sorafenib or another 
molecular targeting agent under clinical trial, TACE with RT 
was recommended based on the treatment outcomes of our 
retrospective studies.
11,12 
We investigated treatment deviations from BCLC recom-
mendations and analyzed the causes of deviations. This 
study was approved by the Investigation and Ethics Com-
mittee for Human Research at Asan Medical Center.
RESULTS
Patient characteristics
The baseline characteristics of the 160 patients are shown 
in Table 2. Of these, 131 (82%) were men of mean age 56.7± 
9.9 years. The etiologies of underlying liver disease were; 
hepatitis B virus (77%), hepatitis C virus (9%), co-infection 
with hepatitis B and C virus (1%), and alcohol (6%). The 
numbers of patients in CTP classes A, B, and C were 137 
(86%), 22 (13%), and 1 (1%), respectively. 
Classification of BCLC stage
Two (1%), 101 (64%), 20 (12.5%), 34 (21.5%) and 3 patients 
(2%) were classified initially to the very early (0), early (A), 
intermediate (B), advanced (C), and terminal (D) BCLC 
stages, respectively. 
Twenty patients (12.5%) had at least one indeterminate 
lesion at initial work-up: 18 patients (18%) of BCLC stage A 
and 2 patients (10%) of stage B. No patient of BCLC 0, 
BCLC C, or BCLC D stages had an indeterminate lesion 
(Table 3). 
The indeterminate lesions of the 18 patients of BCLC A 
were 12 dysplastic nodules in the liver, 2 arterio-portal (AP) 116  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
Table 3. BCLC staging of the study population
BCLC stage Number of patients 
(%)
Obscure case/each 
stage, (%)
Very early (0) 2 (1) 0/2 (0)
Early (A) 101 (64) 18/101 (18)
Intermediate (B) 20 (12.5) 2/20 (10)
Advanced (C) 34 (21.5) 0/34 (0)
Terminal (D) 3 (1) 0/3 (0)
Total 160 (100) 20/160 (12.5)
Reasons for an obscure stage: the presence of an indeterminate 
intrahepatic nodule in 14 (70%) and of an extrahepatic nodule 
in 6 (30%).
Table 4. Reasons for divergence from BCLC recommendations
BCLC stage Recommended Tx  No. of deviation (%) Reason for deviation N (%)
Very early (0) Surgical resection 0/2 (0) - 0 (0)
Early (A) Surgical resection 35/55 (64) Patient refusal  13 (37)
Other indeterminate nodule 9 (25)
Location of HCC 6 (17)
Small FLR 2 (6)
Comorbidity 3 (9)
Hepatitis flare-up 1 (3)
Rupture of HCC 1 (3)
Liver transplantation 33/35 (94) Patient refusal 6 (18)
Absence of donor 22 (67)
Other indeterminate nodule 4 (12)
Large single HCC with portal HTN 1 (3)
RFA/PEIT 1/11 (9) Location of HCC 1 (100)
Intermediate (B) TACE 0/20 (0) - 0 (0)
Advanced (C) Sorafenib or other new agents 27/34 (79) Patient refusal, and/or doctor’s preference 22 (81)
CTP class B  5 (19)
Terminal (D) Supportive 0/3 (0) - 0 (0)
CTP, Child-Turcotte-Pugh; FLR, future liver remnant volume; HCC, hepatocellular carcinoma; HTN, hypertension; PEIT, 
percutaneous ethanol injection therapy; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; Tx, treatment.
shunts, 2 indeterminate nodules in lung, and 2 lymph node 
enlargements of less than 2 cm. Of these 18 patients, 4 
patients with an extrahepatic lesions were candidates for LT. 
However, all refused to undergo LT fearing extrahepatic 
HCC recurrence after LT. In the remaining 14 patients, 
treatment was recommended on the assumption that the 
indeterminate nodules were benign lesions, but 9 patients 
refused surgical resection. In a follow-up test, one suspected 
AP shunt turned out to be HCC. However, 17 (94%) of the 
indeterminate lesions in BCLC A were finally diagnosed as 
benign. Of the two patients of BCLC B stage with an 
indeterminate lesion, one had a lesion in the lung, and in the 
other had a suspected lesion in the right hepatic vein. The 
nodule in the lung proved to be a metastatic lesion during 
follow-up, whereas the lesion in the right hepatic vein was 
finally revealed to be benign. 
Treatment in practice according to BCLC stage
All patients with BCLC 0 (2/2), B (20/20), or D (3/3) 
followed the treatment recommendations of the BCLC 
staging system without deviation. However, 68% patients 
(69/101) with BCLC A and 79% patients (27/34) with 
BCLC C did not receive BCLC recommendations.
Of the 101 with BCLC A, surgical resection was indicated 
in 55, LT in 34, and RFA in 11, according to BCLC recom-
mendations. 
Thirty-five (64%) of 55 patients in whom surgical resection 
was indicated received treatments other than surgical 
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causes of these deviations were patient refusal (37%), the 
presence of an intrahepatic indeterminate nodule (25%), and 
a difficult location for surgical resection (17%). Other 
reasons were insufficient remnant liver volume (6%) and a 
high surgical risk due to comorbidity (9%) (Table 4). 
Of 33 (94%) of 35 patients in whom LT was indicated 23 
underwent RFA and 10 underwent TACE. The causes of 
these deviations were patient refusal due to a financial 
problem (18%), the absence of a donor (67%), the presence 
of an extra-hepatic indeterminate nodule (12%), and the size 
of HCC over than Milan criteria (3%). One patient (9%) of 
11 in whom RFA was indicated underwent TACE due to the 
tumor location. 
Of the 34 patients with BCLC C, 7 (21%) were treated 
with sorafenib or another molecular targeting agent under 
clinical trials. However, the majority (27/34, 79%) including 
5 patients in CTP B were treated with an alternative 
treatment option because they refused or hesitated the use of 
sorafenib (Table 4). The reasons for refusal were high cost 
and a lower expected survival benefit than expectation. These 
27 patients were treated with TACE and/or RT (23/27), 
systemic chemotherapy (2/27), or supportive therapy (2/27).
DISCUSSION
Unlike other solid tumors, the staging of HCC must 
reflect underlying liver function and the degree of tumor 
progression. In this regard, the BCLC staging system has the 
advantages that its recommended treatment options are 
based on HCC stage and that it can predict survival. Many 
studies in Western countries have validated the usefulness of 
this staging system.
13,14 However, it has not been validated in 
Asia where available medical resources, cultural backgrounds 
and socio-economic status are quite different.
In this prospective study, we undertook to determine the 
proportion of HCC patients that followed BCLC treatment 
guidelines. 
Several factors affect the choice of treatment options. 
First, since the BCLC staging system is based on clinical and 
radiological findings, and thus, it is not possible to determine 
exact stage in some patients. This is especially problematic 
for the BCLC staging system because its recommended 
treatment options are dependent on tumor stage. Furthermore, 
in the present study, 12.5% of HCC patients had an inde-
terminate intra- or extra-hepatic lesion and most of these 
lesions were found in early stage patients. Although 90% of 
these lesions ultimately turned out to be benign, the presence 
of such lesions still can affect the choice of invasive 
treatment options, such as LT or surgical resection, since a 
lack of arterial enhancement on dynamic imaging studies or 
hot PET-CT uptake does not necessarily exclude the 
possibility of HCC. However, no recommendations have 
been issued regarding the treatment or the follow up of 
patients with indeterminate lesions. 
Second, LT is not a practically available treatment option 
in Korea, especially in early stage patients in CTP A or B 
with evidence of portal hypertension. In fact, only two 
patients of 34 potential candidates for LT underwent LT. In 
Korea, the donation rate is very low to accommodate LT 
candidates. Although 3,501 candidates for LT have been 
registered at the Korean Network for Organ Sharing 
(KONOS) at the end of 2009, only 233 cadaveric donor LTs 
were performed in 2008. 
Considering that cases with an urgent transplantation 
status (KONOS status 1 and 2a) accounted for 50% in 
cadaveric donor LTs,
15 the likelihood of cadaveric donor LT 
is very low in HCC patients.
16 Furthermore, HCC patients 
cannot have priority for cadaveric donor LT due to a relatively 
good liver function, according to the KONOS guidelines. Of 
course, living donor LT is actively pursued and accounts for 
about 80% of all LTs performed in Korea. Nevertheless, 
candidates for LT annually accumulated to between 400 and 
500. A donor shortage problem also exists in the West, but 
the number of cadaveric donors per million of the population 
ranges between 10 and 35, whereas in Asia it is usually less 
than five. In Korea, the donation rate is extremely low at 
fewer than two donors per million.
17 The lack of 
living-related liver donors and financial problems are also 
important reasons why LT is not performed. Another 
important reason is that patients, especially those with CTP 
A, usually do not want family members to undergo major 
hepatectomy. Therefore, the ideal candidates for surgical 
resection or RFA in the BCLC staging system should be 
modified in Asian countries where LT cannot be widely 
used. 
Third, in addition to overall survival, invasiveness and 
treatment related morbidities are important factors that 
influence treatment choice. The AASLD guidelines say that 
ablation as a first-line treatment option is controversial, and 
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undergo resection or that it used as a bridge to transplantation. 
However, in our series, the most common reason for deviation 
from surgical resection was patient refusal (37%) due to a 
fear of surgery. The presence of an indeterminate nodule 
also significantly influenced patient preferences regarding 
relatively non-invasive treatment options (25%). Collectively, 
only 32% of our early stage patients (32/100) chose the 
BCLC recommended treatment. The strict indications of the 
BCLC for a specific curative treatment option cannot be 
applied to Korean patients with BCLC A, and therefore, 
recommendation of possible curative treatment options such 
as surgical resection, RFA or LT for patients with BCLC 
stage A is a more practical option in Korea.
Another major discrepancy from recommended treatment 
occurred in patients with BCLC C. Although sorafenib has 
proven benefits in BCLC C,
9,10 most patients (81%) did not 
agree to the use of sorafenib. Some patients left the choice to 
the hepatologist in charge, but did not agree to the use of 
sorafenib usually because of a financial problem or a lower 
survival benefit than expected. Most of these patients were 
treated by TACE with/without RT based on our previous 
findings
11 and a guideline issued by the Korean Liver Cancer 
Study Group. Although no prospective randomized trial has 
been conducted, several retrospective analyses have reported 
a median survival of over 18 months in Korean patients with 
1
st or 2
nd branch PV invasion treated by superselective TACE 
or TACE plus RT.
11,12,18,19 Therefore, it is debatable issue 
among Korean physicians as to whether these patients 
should be treated with sorafenib initially despite a lack of 
evidence with other treatment options. It is also controversial 
as to whether sorafenib should be recommended as a 
first-line standard treatment in CTP B patients since 
previous randomized trials included only small numbers of 
CTP B class patients.
9,10 However, other treatment options 
are not usually feasible for these patients.
In the present study, the patient with a single HCC larger 
than 5 cm in diameter and evidence of portal hypertension 
was suggested LT then it would have been contrary to the 
Milan criteria. Even if the University of California at San 
Francisco criteria had been applied, LT would not have been 
recommended because the HCC was greater than 6.5 cm. 
Similarly, no recommendation is made by the BCLC staging 
system regarding the classification and treatment of HCC 
patients with a ruptured tumor or major bile duct invasion. 
Accordingly, the BCLC staging system cannot be applied to 
all HCC patients in Korea where the prevalence of HCC is 
high and many high-risk patients are not received 
surveillance program.
Summarizing, although the BCLC staging system has 
been validated in the West, provides recommended treatment 
options according to HCC stage, and can predict survival, it 
is difficult to  apply to HCC patients in Korea. Even after 
excluding treatment divergences due to patient preferences, 
only 66% of patients were treated in accord with the BCLC 
guidelines in our cohort. The main reasons for these 
discrepancies were an extreme shortage of liver donors and 
the financial problems posed by LT, a preference for a less 
invasive treatment, high cost, and the low anticipated 
survival benefit of sorafenib. Furthermore, we recommend 
that future studies be conducted to determine recommended 
treatment options in patients with an indeterminate intra- or 
extra-hepatic lesion and in the few patients in whom stage 
cannot be determined by the BCLC staging system. Accordingly, 
treatment guidelines are required for HCC patients that 
accurately reflect the particular situations in Korea.
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